• US: +1 9176726599
  • Login

Adoptive Cell Therapy Market Status (2016-2020) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2021-2027

Format: PDF | Pages: 305 | Report ID: MRS1129


Report Description

The global Adoptive Cell Therapy market size is estimated at USD 11,440.7 million in 2020, expanding at a CAGR of 30.4% from 2021-to 2027 to reach 21,440.7 Million USD in 2027.

Market Dynamics

Adoptive cell therapy (ACT) is a type of immunotherapy in which a patient is given T cells (a type of immune cell) to help the body fight diseases such as cancer. Chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor-infiltrating lymphocytes (TILs), and natural killer (NK) cells are all examples of adoptive cell therapy. Adoptive cell therapy involves the use of large numbers of immune cells grown in the lab before being administered to the body to fight cancer. Immune cells that naturally recognize melanoma are sometimes used, while other times they are modified to recognize and kill melanoma cells. T-cell transfer therapy and cellular immunotherapy are other terms for adoptive cell therapy.

Regional Insights

Among regions, North America is estimated to hold a dominant position in the global adoptive cell therapy market in 2022 owing to key players in the market focusing on product approvals for adoptive cell therapy. For example, NantKwest Inc., a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the company's immune system using natural killer (NK) cells to treat cancer, infectious diseases, and other diseases, announced in June 2021 that the company's t-haNK is a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins.

Due to key players in the market focusing on growth strategies such as acquisition, Asia Pacific is expected to exhibit a higher CAGR in the global adoptive cell therapy market over the forecast period. For example, Laurus Labs, an India-based pharma and biotech company, announced in November 2021 that it had signed an agreement to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company developing an indigenous CAR T-cell therapy for treating specific types of blood cancers. For a cash consideration of approximately 46 crores (US $ 460 million), Laurus Labs will acquire a 26.62 percent (fully diluted) stake in ImmunoACT.

Segment Insights

The Adoptive Cell Therapy market is fragmented into type, application, and end-user segments. Based on the type, the CAR-T is anticipated to dominate the market. Based on application, lymphoma is anticipated to have a higher growth rate in the coming years. By end-user, the hospital segment is expected to hold the majority of the market share.

Competitive Insights

Key players in the global adoptive cell therapy market are focusing on growth strategies such as product launch, collaboration, and fundraising, which are expected to drive market growth over the forecast period. Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company, announced in January 2021 that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.

The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses the market size and forecast of Adoptive Cell Therapy by type, application, end-user, and region. In addition, this report introduces the market competition situation among the vendors, and the company profile, besides, market price analysis, and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Novartis AG
  • Gilead Sciences, Inc
  • Castle Creek Biosciences, Inc
  • Lineage Cell Therapeutics, Inc.
  • Transgene SA
  • Cellectis
  • ImmunityBio, Inc
  • Sorrento Therapeutics
  • bluebird bio, Inc
  • Arcellx
  • Sana Biotechnology, Inc
  • Biodesix, Inc
  • Laurus Labs

Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • CAR-T
  • TCR-T
  • NK
  • TIL

Application Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Lymphoma
  • Leukemia
  • Others

End-User Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Hospitals
  • Cancer Treatment Centres
  • Others

Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina, etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa, etc.)

Frequently Asked Questions

The global Adoptive Cell Therapy market size is estimated at USD 11,440.7 million in 2020, expanding at a CAGR of 30.4% from 2021-to 2027 to reach 21,440.7 Million USD in 2027.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Adoptive Cell Therapy market size is expanding at a CAGR of 30.4% from 2021-to 2027 to reach 21,440.7 Million USD in 2027.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
Key players in the global adoptive cell therapy market are focusing on growth strategies such as product launch, collaboration, and fundraising, which are expected to drive market growth over the forecast period. Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company, announced in January 2021 that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.